Kodu・Aktsiate loetelu・Viking Therapeutics Inc

Viking Therapeutics Inc

Suletud

SektorTervishoid

32.81 0.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.47

Max

33.51

Põhinäitajad
By Trading Economics
Sissetulek	30M -128M
Aktsiakasum	-1.1
Töötajad	65
EBITDA	30M -128M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+182.37% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	21. okt 2026

Turustatistika
By TradingEconomics
Turukapital	-245M 3.8B
Eelmine avamishind	32.1
Eelmine sulgemishind	32.81

Uudiste sentiment

By Acuity

50%

175 / 340 Pingereas Healthcare

Viking Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3. aug 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31. juuli 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30. juuli 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29. juuli 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28. juuli 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27. juuli 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25. juuli 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24. juuli 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23. juuli 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22. juuli 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Võrdlus sarnastega

Hinnamuutus

Viking Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

182.37% tõus

12 kuu keskmine prognoos

Keskmine 92.08 USD 182.37%

Kõrge 114 USD

Madal 70 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Viking Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Viking Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

175 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.